Attached files
file | filename |
---|---|
10-K - ANNUAL REPORT - Tamir Biotechnology, Inc. | alfacell_10k-073109.htm |
EX-23.1 - CONSENT OF J.H. COHN LLP - Tamir Biotechnology, Inc. | ex23-1.htm |
EX-32.1 - CERTIFICATION - Tamir Biotechnology, Inc. | ex32-1.htm |
EX-31.2 - CERTIFICATION - Tamir Biotechnology, Inc. | ex31-2.htm |
EX-31.1 - CERTIFICATION - Tamir Biotechnology, Inc. | ex31-1.htm |
EX-10.51 - TERMINATION AGREEMENT - Tamir Biotechnology, Inc. | ex10-51.htm |
EX-10.52 - AMENDMENT TO RETIREMENT AGREEMENT - Tamir Biotechnology, Inc. | ex10-52.htm |
Exhibit
23.2
CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board
of Directors
Alfacell
Corporation:
We
consent to the incorporation by reference in the registration statements (Nos.
333-112865 and 333-136678) on Form S-3 and (Nos. 33-81308, 333-110074 and
333-112866) on Form S-8 of Alfacell Corporation of our report dated November 4,
2002, with respect to the related statements of operations, stockholders' equity
(deficiency), and cash flows of Alfacell Corporation for the period from August
24, 1981 (date of inception) to July 31, 2002, which report appears in the July
31, 2009 annual report on Form 10-K of Alfacell Corporation. Our report dated
November 4, 2002, as it relates to the financial statements for the period from
August 24, 1981 (date of inception) to July 31, 2002, is based on the report of
other auditors who have ceased operations as to the amounts included therein for
the period from August 24, 1981 (date of inception) to July 31,
1992.
Our
report dated November 4, 2002 contains an explanatory paragraph that states that
the Company has suffered recurring losses from operations, has a working capital
deficit and has limited liquid resources which raise substantial doubt about its
ability to continue as a going concern. The financial statements do not include
any adjustments that might result from the outcome of that
uncertainty.
/s/
KPMG LLP
Short
Hills, New Jersey
November
13, 2009
|